Hims Hers Health Inc (HIMS)vsUnited Therapeutics Corporation (UTHR)
HIMS
Hims Hers Health Inc
$28.00
-4.21%
HEALTHCARE · Cap: $6.05B
UTHR
United Therapeutics Corporation
$549.87
+0.40%
HEALTHCARE · Cap: $23.64B
Smart Verdict
WallStSmart Research — data-driven comparison
United Therapeutics Corporation generates 34% more annual revenue ($3.17B vs $2.37B). UTHR leads profitability with a 40.6% profit margin vs -0.6%. HIMS appears more attractively valued with a PEG of 2.16. UTHR earns a higher WallStSmart Score of 57/100 (C).
HIMS
Avoid27
out of 100
Grade: F
UTHR
Buy57
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-7.0%
Fair Value
$25.38
Current Price
$28.00
$2.62 premium
Margin of Safety
+2.5%
Fair Value
$487.82
Current Price
$549.87
$62.05 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Keeps 41 of every $100 in revenue as profit
Strong operational efficiency at 41.7%
Safe zone — low bankruptcy risk
Every $100 of equity generates 22 in profit
Areas to Watch
Expensive relative to growth rate
Trading at 14.5x book value
3.8% revenue growth
Distress zone — elevated risk
Expensive relative to growth rate
Revenue declined 1.6%
Earnings declined 12.2%
Comparative Analysis Report
WallStSmart ResearchBull Case : HIMS
HIMS has a balanced fundamental profile.
Bull Case : UTHR
The strongest argument for UTHR centers on Profit Margin, Operating Margin, Altman Z-Score. Profitability is solid with margins at 40.6% and operating margin at 41.7%.
Bear Case : HIMS
The primary concerns for HIMS are PEG Ratio, Price/Book, Revenue Growth. Debt-to-equity of 2.54 is elevated, increasing financial risk.
Bear Case : UTHR
The primary concerns for UTHR are PEG Ratio, Revenue Growth, EPS Growth.
Key Dynamics to Monitor
HIMS profiles as a turnaround stock while UTHR is a declining play — different risk/reward profiles.
HIMS carries more volatility with a beta of 2.42 — expect wider price swings.
HIMS is growing revenue faster at 3.8% — sustainability is the question.
UTHR generates stronger free cash flow (363M), providing more financial flexibility.
Bottom Line
UTHR scores higher overall (57/100 vs 27/100), backed by strong 40.6% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Hims Hers Health Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Hims & Hers Health, Inc. operates a multi-specialty telehealth platform that connects consumers with licensed healthcare professionals. The company is headquartered in San Francisco, California.
Visit Website →United Therapeutics Corporation
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
United Therapeutics Corporation, a biotechnology company, is dedicated to the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company is headquartered in Silver Spring, Maryland.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?